Stuart Therapeutics Welcomes New Board Members
Stuart Therapeutics is excited to announce the addition of two prominent leaders in the field of ophthalmology, enhancing their Board of Directors as they move towards significant developments in therapeutics.
New Appointees Bring Vast Experience
Tracy Valorie and Jason Werner have been appointed to the Board, increasing the total board membership to five. This strategic move follows the passing of Robert O. Baratta, MD, and the recent resignation of retired US Representative Diane Black, RN.
Tracy Valorie's Background
Tracy Valorie is a well-respected figure in the pharmaceutical and biotech industry, serving as a strategic business consultant and owner of TMV Associates LLC since 2019. With over 30 years of dedicated experience, she held the position of Senior Vice President at Bausch + Lomb, where she was pivotal in managing the U.S. pharmaceutical divisions. Prior to that, Tracy led the ophthalmology sector at Pfizer, showcasing her ability to drive growth and innovation in the industry. Her extensive network and expertise in commercial development will be invaluable as Stuart Therapeutics navigates its next phases of growth.
Jason Werner's Experience
Executively leading Sightstream Biotherapeutics, Jason Werner brings a wealth of expertise in regenerative ophthalmic therapies. His track record includes playing crucial roles at Eyevance Pharmaceuticals and Alimera, where his leadership guided the company through transformative sales and development in the highly competitive biotech arena. With a degree in business administration, Jason's insights into commercial strategies will significantly benefit Stuart Therapeutics as they aim to broaden their therapeutic offerings.
Strategic Transition for Growth
Expressing his enthusiasm, Eric Schlumpf, President and CEO of Stuart Therapeutics, stated, "The addition of Tracy and Jason to our Board signifies a pivotal moment for our company. Their combined experiences will be critical as we transition into an exciting phase of growth and development in ophthalmology therapeutics. We also acknowledge the significant contributions made by Bob Baratta and Diane Black in shaping our organization during its formative years."
Vision for Future Impact
Tracy Valorie voiced her excitement about joining the board, highlighting her eagerness to contribute to innovative treatments that aim to make a lasting impact on patients with ophthalmic disorders. She is committed to leveraging her experience to ensure successful collaborations that will propel the company's achievements in the sector.
Jason Werner added, "This is a pivotal time for Stuart Therapeutics. With anticipated milestone developments on the horizon, I am eager to work closely with Tracy and Eric to ensure that our pipeline offerings successfully reach patients while maximizing shareholder value for Stuart and its investors."
About Stuart Therapeutics, Inc.
Stuart Therapeutics, Inc. is a dynamic, clinical-stage entity focusing on ophthalmic therapies. Their flagship asset, ST-100, is nearing completion of its Phase 3 trial, with expectations set for a readout early next year. Additionally, the company is advancing innovative programs targeting retinal diseases and myopia, coupled with a collaboration for neuroprotection in glaucoma through a partnership with Glaukos Corp.
Frequently Asked Questions
Who are the new board members at Stuart Therapeutics?
The new board members are Tracy Valorie and Jason Werner, both experienced leaders in ophthalmology and biotechnology.
What is the primary focus of Stuart Therapeutics?
Stuart Therapeutics specializes in developing clinical-stage therapies for ophthalmic conditions, focusing on innovative solutions for eye diseases.
Why did previous board members step down?
Robert O. Baratta passed away, and Diane Black recently resigned. Their contributions were significant during the company's early stages.
What qualifications do Tracy Valorie and Jason Werner bring?
Valorie has extensive experience in pharmaceutical management, and Werner has a strong background in biotech operations, both crucial for guiding Stuart's future.
What are the next steps for Stuart Therapeutics following this announcement?
The focus will be on progressing their lead asset ST-100 through clinical trials and enhancing their therapeutic offerings in ophthalmology.
